Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
336 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Mantle Cell Lymphoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H1 2015', provides an overview of the Mantle Cell Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Mantle Cell Lymphoma Overview 9 Therapeutics Development 10 Pipeline Products for Mantle Cell Lymphoma - Overview 10 Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 11 Mantle Cell Lymphoma - Therapeutics under Development by Companies 12 Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 16 Mantle Cell Lymphoma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Mantle Cell Lymphoma - Products under Development by Companies 20 Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 24 Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 25 AbbVie Inc. 25 Accentia Biopharmaceuticals, Inc. 26 Actinium Pharmaceuticals, Inc. 27 Advancell 28 Affimed Therapeutics AG 29 Amgen Inc. 30 Astellas Pharma Inc. 31 Astex Pharmaceuticals, Inc. 32 Bayer AG 33 Bristol-Myers Squibb Company 34 Celgene Corporation 35 Celldex Therapeutics, Inc. 36 Eisai Co., Ltd. 37 Eli Lilly and Company 38 EpiZyme, Inc. 39 Gilead Sciences, Inc. 40 GlaxoSmithKline plc 41 ImmunoGen, Inc. 42 Incyte Corporation 43 Infinity Pharmaceuticals, Inc. 44 Johnson & Johnson 45 Karyopharm Therapeutics, Inc. 46 Kite Pharma, Inc. 47 MedImmune, LLC 48 Merck & Co., Inc. 49 Millennium Pharmaceuticals, Inc. 50 MorphoSys AG 51 Nordic Nanovector AS 52 Novartis AG 53 Onconova Therapeutics, Inc. 54 Onyx Pharmaceuticals, Inc. 55 Pfizer Inc. 56 Pharmacyclics, Inc. 57 Portola Pharmaceuticals, Inc. 58 Seattle Genetics, Inc. 59 Sevion Therapeutics, Inc. 60 Stemline Therapeutics, Inc. 61 Teva Pharmaceutical Industries Limited 62 TG Therapeutics, Inc. 63 Mantle Cell Lymphoma - Therapeutics Assessment 64 Assessment by Monotherapy Products 64 Assessment by Combination Products 65 Assessment by Target 66 Assessment by Mechanism of Action 69 Assessment by Route of Administration 72 Assessment by Molecule Type 74 Assessment by Molecule Type 74 Drug Profiles 76 13197 - Drug Profile 76 abemaciclib - Drug Profile 78 abexinostat hydrochloride - Drug Profile 79 acadesine - Drug Profile 81 ACP-196 - Drug Profile 83 AFM-11 - Drug Profile 84 agatolimod sodium - Drug Profile 85 alisertib - Drug Profile 88 AMG-319 - Drug Profile 92 AT-7519 - Drug Profile 93 bendamustine hydrochloride - Drug Profile 96 Betalutin - Drug Profile 99 blinatumomab - Drug Profile 101 BLyS-gel - Drug Profile 104 BMS-986016 - Drug Profile 105 bortezomib - Drug Profile 106 buparlisib hydrochloride - Drug Profile 112 carfilzomib - Drug Profile 116 CC-122 - Drug Profile 120 Cell Therapy for Oncology - Drug Profile 122 Cell Therapy to Target CD19 for Oncology - Drug Profile 123 Cell Therapy to Target CD19 for Oncology - Drug Profile 124 Cell Therapy to Target CD20 for Chemotherapy Resistant Cancers - Drug Profile 125 CEP-9722 - Drug Profile 126 cerdulatinib - Drug Profile 127 copanlisib - Drug Profile 128 dasiprotimut-T - Drug Profile 131 denintuzumab mafodotin - Drug Profile 133 duvelisib - Drug Profile 134 E-7449 - Drug Profile 136 EPZ-015666 - Drug Profile 137 FROST-400 - Drug Profile 138 GS-9973 - Drug Profile 139 ibrutinib - Drug Profile 140 ibrutinib + ublituximab + TGR-1202 - Drug Profile 146 idelalisib - Drug Profile 147 IMGN-529 - Drug Profile 150 INA-01 - Drug Profile 151 INCB-39110 - Drug Profile 152 INCB-40093 - Drug Profile 154 ixazomib citrate - Drug Profile 155 KTE-C19 CAR - Drug Profile 158 lenalidomide - Drug Profile 160 MEDI-0680 - Drug Profile 164 MEDI-551 - Drug Profile 165 MGD-011 - Drug Profile 167 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 168 Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 169 MOR-208 - Drug Profile 170 moxetumomab pasudotox - Drug Profile 172 ON-123300 - Drug Profile 174 palbociclib - Drug Profile 175 pevonedistat hydrochloride - Drug Profile 179 ribociclib - Drug Profile 181 selinexor - Drug Profile 184 SGN-CD70A - Drug Profile 188 SL-101 - Drug Profile 189 SNS-01T - Drug Profile 190 sotrastaurin acetate - Drug Profile 191 TGR-1202 - Drug Profile 193 tisagenlecleucel-T - Drug Profile 195 tretinoin - Drug Profile 197 ublituximab - Drug Profile 198 varlilumab - Drug Profile 200 venetoclax - Drug Profile 202 vorinostat - Drug Profile 205 Mantle Cell Lymphoma - Recent Pipeline Updates 209 Mantle Cell Lymphoma - Dormant Projects 314 Mantle Cell Lymphoma - Discontinued Products 316 Mantle Cell Lymphoma - Product Development Milestones 317 Featured News & Press Releases 317 Appendix 330 Methodology 330 Coverage 330 Secondary Research 330 Primary Research 330 Expert Panel Validation 330 Contact Us 330 Disclaimer 331
List of Tables Number of Products under Development for Mantle Cell Lymphoma, H1 2015 15 Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2015 16 Number of Products under Development by Companies, H1 2015 18 Number of Products under Development by Companies, H1 2015 (Contd..1) 19 Number of Products under Development by Companies, H1 2015 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2015 21 Comparative Analysis by Late Stage Development, H1 2015 22 Comparative Analysis by Clinical Stage Development, H1 2015 23 Comparative Analysis by Early Stage Development, H1 2015 24 Products under Development by Companies, H1 2015 25 Products under Development by Companies, H1 2015 (Contd..1) 26 Products under Development by Companies, H1 2015 (Contd..2) 27 Products under Development by Companies, H1 2015 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2015 29 Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H1 2015 30 Mantle Cell Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2015 31 Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 32 Mantle Cell Lymphoma - Pipeline by Advancell, H1 2015 33 Mantle Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015 34 Mantle Cell Lymphoma - Pipeline by Amgen Inc., H1 2015 35 Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2015 36 Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 37 Mantle Cell Lymphoma - Pipeline by Bayer AG, H1 2015 38 Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2015 39 Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H1 2015 40 Mantle Cell Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2015 41 Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2015 42 Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H1 2015 43 Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2015 44 Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2015 45 Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H1 2015 46 Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2015 47 Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H1 2015 48 Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 49 Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2015 50 Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 51 Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2015 52 Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2015 53 Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2015 54 Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 55 Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H1 2015 56 Mantle Cell Lymphoma - Pipeline by Nordic Nanovector AS, H1 2015 57 Mantle Cell Lymphoma - Pipeline by Novartis AG, H1 2015 58 Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2015 59 Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 60 Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H1 2015 61 Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015 62 Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2015 63 Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2015 64 Mantle Cell Lymphoma - Pipeline by Sevion Therapeutics, Inc., H1 2015 65 Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2015 66 Mantle Cell Lymphoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 67 Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2015 68 Assessment by Monotherapy Products, H1 2015 69 Assessment by Combination Products, H1 2015 70 Number of Products by Stage and Target, H1 2015 72 Number of Products by Stage and Mechanism of Action, H1 2015 75 Number of Products by Stage and Route of Administration, H1 2015 78 Number of Products by Stage and Molecule Type, H1 2015 80 Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 214 Mantle Cell Lymphoma - Dormant Projects, H1 2015 319 Mantle Cell Lymphoma - Dormant Projects (Contd..1), H1 2015 320 Mantle Cell Lymphoma - Discontinued Products, H1 2015 321
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
